Meanwhile, anti-CD38 MoAb could contribute to myeloma cell death by not only binding to myeloma cells but also several immune cells, leading to reduced abundance of regulatory T cells (Tregs) and activation of cytotoxic T lymphocytes and natural killer (NK) cells [22]. This evidence concerns the gene CD38 and plasma cell myeloma.